MedTrace Logo

Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults.

NCT07314593 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-01-02

No results posted yet for this study

Summary

The purpose of this study is to investigate whether fish oil containing free fatty acids affects people's susceptibility to viral infections such as colds, influenza, and COVID-19, as well as the course of these illnesses. Omega Cold is purified fish oil with 2% added free fatty acids, making it similar in that respect to less-purified fish oils. Participants aged 18-80 in generally good health will be recruited through Matís' consumer mailing list and social media advertisements. A total of 400 participants are planned: 100 in the winter of 2025-2026 and 300 in the winter of 2026-2027. Participants will be randomly assigned to two equal groups. One group will take Omega Cold orally twice a day for four months, while the other receives a placebo (vegetable oil) taken in the same way. They will not be asked to change any other habits. All participants will report weekly on their health and any cold or flu symptoms during the time they take the oil, using short questionnaires. The study is scheduled to begin in December 2025, when the oil will be sent to participants.

Conditions

Interventions

DIETARY_SUPPLEMENT

Omega-3 oil with 2% Free Fatty Acids

Omega-3 oil enriched with Free Fatty Acids (2%) for oral intake

DIETARY_SUPPLEMENT

Vegatable oil

Vegetable oil as placebo

Sponsors & Collaborators

  • Matis ohf.

    collaborator UNKNOWN

  • Lipid Pharmaceuticals ehf.

    collaborator UNKNOWN

  • Landspitali University Hospital

    lead OTHER

Principal Investigators

  • Magnús Gottfreðsson, MD, PhD · Landspitali, University of Iceland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-19
Primary Completion
2027-04-30
Completion
2027-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07314593 on ClinicalTrials.gov